Evidence map›Paper›PMID 38270746›Full record

ReviewMolecular biology reports2024

Key processes in tumor metastasis and therapeutic strategies with nanocarriers: a review.

Hongjie Li, Haiqin Huang, Haining Tan, Qitao Jia, Weina Song, Qingdong Zhang, Baolong Zhou, Jingkun Bai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongjie LiSchool of Clinical Medicine, Weifang Medical University, 261053, Weifang, China.
Haiqin HuangSchool of Bioscience and Technology, Weifang Medical University, 261053, Weifang, China.
Haining TanNational Glycoengineering Research Center, Shandong University, 250012, Jinan, China.
Qitao JiaSchool of Bioscience and Technology, Weifang Medical University, 261053, Weifang, China.
Weina SongDepartment of Pediatric Respiratory and Critical Care, Qilu Hospital of Shandong University Dezhou Hospital, 253000, Dezhou, China.
Qingdong ZhangSchool of Bioscience and Technology, Weifang Medical University, 261053, Weifang, China. zhangqingdong@wfmc.edu.cn.
Baolong ZhouSchool of Pharmacy, Weifang Medical University, 261053, Weifang, China. zhoubaolong@wfmc.edu.cn.
Jingkun BaiSchool of Bioscience and Technology, Weifang Medical University, 261053, Weifang, China. jkbaizg@163.com.

Funding

Natural Science Foundation of Shandong Province ZR2023MC122)Open Projects Fund of NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine 2021QRECM03
6 · The paper itself

Abstract

Cancer metastasis is the leading cause of cancer-related death. Metastasis occurs at all stages of tumor development, with unexplored changes occurring at the primary site and distant colonization sites. The growing understanding of the metastatic process of tumor cells has contributed to the emergence of better treatment options and strategies. This review summarizes a range of features related to tumor cell metastasis and nanobased drug delivery systems for inhibiting tumor metastasis. The mechanisms of tumor metastasis in the ideal order of metastatic progression were summarized. We focus on the prominent role of nanocarriers in the treatment of tumor metastasis, summarizing the latest applications of nanocarriers in combination with drugs to target important components and processes of tumor metastasis and providing ideas for more effective nanodrug delivery systems.

Indexed as

Drug Delivery SystemsNeoplasmsHumansDrug deliveryNanotherapeuticsTargeted therapiesTumor metastasisTumor microenvironment

Identifiers

PMID38270746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.